pediatric | Aplastic Anemia & MDS International Foundation

pediatric

2021 March for Marrow California - Virtual Walk and 5K

Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting

Event Date: 
Sat, 04/24/2021 to Sat, 05/01/2021
Community Event Type: 

2021 March for Marrow Texas - VIRTUAL Walk and 5K

Join together virtually with fellow patients, families, caregivers, and friends to raise awareness for

Event Date: 
Sat, 03/27/2021 to Sat, 04/03/2021
Community Event Type: 

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.

Seth Rotz, MD

Rotz, Seth
Physician
Cleveland Clinic Children's Hospital

Dr. Rotz is a physician, Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children’s Hospital and Assistant Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Member, Cancer Prevention Control & Population Research Program, Case Comprehensive Cancer Center.

A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

This study will enroll participants aged 12 years or older with a body weight >= 40 kg diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 200 participants will be randomized in a 2:1 ratio into the following regimens: [1] Crovalimab; [2]

Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium

Author(s): 
Nakano TA, Lau BW, Dickerson KE, Wlodarski M, Pollard J, Shimamura A, Hofmann I, Sasa G, Elghetany T, Cada M, Dror Y, Ding H, Allen SW, Hanna R, Campbell K, Olson TS
Primary Author: 
Nakano TA
Journal Title: 
Pediatric Blood & Cancer
Original Publication Date: 
Aug 2020

Background: